Literature DB >> 17151701

Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells.

D Iglesias-Serret1, M de Frias, A F Santidrián, L Coll-Mulet, A M Cosialls, M Barragán, A Domingo, J Gil, G Pons.   

Abstract

Glucocorticoids induce apoptosis in chronic lymphocytic leukemia (CLL) cells through a caspase-dependent mechanism. However, their mechanism of action remains unknown. We have studied the regulation of the proapoptotic BH3-only Bcl-2 interacting mediator of cell death (BIM) in CLL cells. We demonstrate that glucocorticoids upregulate BIM at protein and mRNA levels. We have investigated the ability of different survival signals, such as 12-O-tetradecanoylphorbol 13-acetate (TPA), stromal cell-derived factor-1alpha (SDF-1alpha), interleukin 4 (IL-4) and B-cell receptor (BCR) activation, to influence the levels of BIM and its induction by glucocorticoids. TPA downregulates BIM(EL) by extracellular signal-regulated kinase (ERK)-mediated BIM phosphorylation and further proteasome-mediated degradation. However, SDF-1alpha and BCR activation induce transient BIM phosphorylation, without protein degradation. Proteasome inhibitors do not modify the levels of BIM with respect to untreated cells. However, they induce apoptosis and inhibit TPA-induced BIM(EL) degradation, leading to its accumulation. In conclusion, the results implicate BIM in glucocorticoid-induced apoptosis in CLL cells. BIM(EL) phosphorylation through the ERK pathway targets the protein for proteasomal degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151701     DOI: 10.1038/sj.leu.2404483

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Glycogen synthase kinase-3β is involved in ligand-dependent activation of transcription and cellular localization of the glucocorticoid receptor.

Authors:  Camila Rubio-Patiño; Claudia M Palmeri; Alba Pérez-Perarnau; Ana M Cosialls; Cristina Moncunill-Massaguer; Diana M González-Gironès; Lluís Pons-Hernández; José M López; Francesc Ventura; Joan Gil; Gabriel Pons; Daniel Iglesias-Serret
Journal:  Mol Endocrinol       Date:  2012-07-06

2.  Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors:  Farrukh T Awan; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami J Maddocks; Ellen J Sass; Margaret S Lucas; Weihong Chase; Sharon Waymer; Yonghua Ling; Yao Jiang; Mitch A Phelps; John C Byrd; David M Lucas; Jennifer A Woyach
Journal:  Leuk Lymphoma       Date:  2015-03-11

Review 3.  Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean?

Authors:  Mario Noti; Daniel Sidler; Thomas Brunner
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 4.  End-point effector stress mediators in neuroimmune interactions: their role in immune system homeostasis and autoimmune pathology.

Authors:  Mirjana Dimitrijevic; Stanislava Stanojevic; Natasa Kustrimovic; Gordana Leposavic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

5.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

6.  Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.

Authors:  Aybike Birerdinc; Elizabeth Nohelty; Andrey Marakhonov; Ganiraju Manyam; Ivan Panov; Stephanie Coon; Eugene Nikitin; Mikhail Skoblov; Vikas Chandhoke; Ancha Baranova
Journal:  Tumour Biol       Date:  2009-12-18

7.  Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Authors:  Yicheng Mao; Georgia Triantafillou; Erin Hertlein; William Towns; Matthew Stefanovski; Xiaokui Mo; David Jarjoura; Mitch Phelps; Guido Marcucci; Ly James Lee; David M Goldenberg; Robert J Lee; John C Byrd; Natarajan Muthusamy
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

Review 8.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

9.  The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia.

Authors:  C Ploner; J Rainer; H Niederegger; M Eduardoff; A Villunger; S Geley; R Kofler
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

10.  Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Authors:  T Melarangi; J Zhuang; K Lin; N Rockliffe; A G Bosanquet; M Oates; J R Slupsky; A R Pettitt
Journal:  Cell Death Dis       Date:  2012-08-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.